Evaluation of new or repurposed treatments for COVID-19: protocol for the phase Ib/IIa DEFINE trial platform
Introduction COVID-19 is a new viral-induced pneumonia caused by infection with a novel coronavirus, SARS-CoV-2. At present, there are few proven effective treatments. This early-phase experimental medicine protocol describes an overarching and adaptive trial designed to provide safety data in patie...
Saved in:
| Main Authors: | Ahsan Akram, Tom Quinn, Jean Antonelli, Oliver Koch, Kevin Dhaliwal, Nik Hirani, Erin Gaughan, Annya Bruce, Vikki Young, Joanne Mair, Claire Mackintosh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/12/e054442.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nodal staging score: A tool to quantify the number of lymph nodes for examination and predict survival in IB–IIA cervical cancer
by: Hongrui Qiu, et al.
Published: (2024-12-01) -
Ib2-IIa期巨块型宫颈癌热疗联合同步放化疗与同步放化疗的疗效比较
by: 徐西伟
Published: (2016-01-01) -
Comparison of sustainable life cycle assessment on building construction methods: IBS versus conventional
by: Nik Mazlan Nik Muhammad Akif, et al.
Published: (2025-01-01) -
Ancestors of the Minoan sword: Early Minoan IB long daggers from Hagia Photia, Crete
by: Costis Davaras, et al.
Published: (2023-09-01) -
Development of Class IIa Bacteriocins as Therapeutic Agents
by: Christopher T. Lohans, et al.
Published: (2012-01-01)